Dibenzepin
From Wikipedia, the free encyclopedia
 |
|
|
Dibenzepin
|
|
| Systematic (IUPAC) name | |
| 10-(2-(dimethylamino)ethyl)-5-methyl-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C18H21N3O |
| Mol. mass | 295.379 |
| Pharmacokinetic data | |
| Bioavailability | 25% (oral) |
| Metabolism | Hepatic, demethylation |
| Half life | 5 h |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
POM/Rx |
| Routes | Oral |
Dibenzepin (Noveril) is a noradrenaline reuptake inhibitor, an H1 receptor antagonist and a muscarinic antagonist. It is indicated for use as an antidepressant[1]. It has similar properties to imipramine and is considered a weakly- or non-sedative, second generation tricyclic antidepressant.
[edit] Referencnes
|
|||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
